Immunic, Inc. (IMUX) Covered Calls

You can sell covered calls on Immunic, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for IMUX (prices last updated Tue 4:16 PM ET):

Immunic, Inc. (IMUX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
0.69 -0.01 0.70 0.72 962K - 0.1
Covered Calls For Immunic, Inc. (IMUX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Jul 18 2.5 0.00 0.72 0.0% 0.0%
Aug 15 2.5 0.00 0.72 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.